SCHEMBL7346207

SCHEMBL7346207

NN=Cc1ccc2cc(C(=O)Nc3cncnc3)ccc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCAT2 O15382 1/20 0.47
KDM4E B2RXH2 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
PLAU P00749 7/20 0.43
PLG P00747 4/20 0.41
KLKB1 P03952 4/20 0.41
PRSS1 P07477 4/20 0.41
F2 P00734 3/20 0.41
PLAT P00750 3/20 0.41
KLK1 P06870 1/20 0.41
DEGS1 O15121 1/20 0.40
GRM5 P41594 2/20 0.40
DNM1 Q05193 1/20 0.39
PTPN11 Q06124 1/20 0.39
LCK P06239 1/20 0.39
KIT P10721 1/20 0.39
SRC P12931 1/20 0.39
KDR P35968 1/20 0.39
MAPK14 Q16539 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7336457 0.84 NPC1 (0.53) KDM4ENPC1RAB9APLAUPLG
SCHEMBL7340329 0.82 PLAU (0.63) BCAT2NPC1RAB9APLAUPLG
SCHEMBL7340171 0.81 RAB9A (0.44) KDM4ENPC1RAB9APLAUPLG
SCHEMBL7335937 0.81 DEGS1 (0.57) KDM4ENPC1RAB9ADEGS1DNM1
SCHEMBL7346861 0.80 SIRT2 (0.53) KDM4ENPC1RAB9ADEGS1LCK
SCHEMBL7337814 0.79 MAP4K4 (0.60) KDM4ENPC1RAB9A
SCHEMBL7340942 0.79 PLAU (0.67) NPC1RAB9APLAUPLGKLKB1
SCHEMBL7337311 0.79 PLAU (0.58) KDM4ENPC1RAB9APLAUPLG
SCHEMBL7343081 0.79 PLAU (0.67) NPC1RAB9APLAUPLGKLKB1
SCHEMBL7345240 0.79 PLAU (0.64) KDM4ENPC1RAB9APLAUPLG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 BCAT2 1105/4885KDM4E 4285/4885NPC1 2478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.